The impact of ocrelizumab on health-related quality of life in individuals with multiple sclerosis
Authors:
- Bonnie I GlanzBGBonnie I Glanz
- Jonathan ZurawskiJZJonathan Zurawski
- Emily C CasadyECEmily C Casady
- Rebecca ShamahRSRebecca Shamah
- Tanuja ChitnisTCTanuja Chitnis
Open Access
- 1 April 2021
- journal article
- research article
- Published by SAGE Publications in Multiple Sclerosis Journal – Experimental, Translational and Clinical
- Vol. 7 (2)
Abstract
Background: Ocrelizumab is approved for the treatment of both relapsing and progressive multiple sclerosis (MS). Objective: To examine the impact of ocrelizumab on health-related quality of life (HRQOL) in individuals with MS. Methods: Ninety-eight individuals with relapsing and 32 with progressive MS were enrolled. Participants were administered a battery of patient-reported outcome (PRO) measures at their first ocrelizumab infusion, and infusions at 6 and 12 months. PRO measures included the Medical Outcomes Study SF-36 and Neuro-QoL. Results: At baseline, participants had low mean scores across HRQOL domains. After 12 months, increases were observed on SF-36 Role-Physical, General Health, Vitality, Role-Emotional, Mental health and Mental Component Summary. On Neuro-QoL, improvements were seen in Positive Affect, Anxiety, Emotional and Behavioral Dyscontrol and Fatigue. Several demographic and clinical characteristics were associated with HRQOL at baseline. The strongest associations were between physical HRQOL measures and measures of MS disability. Associations between the longitudinal change in HRQOL scores and baseline demographic and clinical characteristics were mild. Conclusions: We observed significant improvements across multiple mental HRQOL domains at 12 months in individuals treated with ocrelizumab. These findings support the use of HRQOL measures to provide a subjective measure of treatment impact that complements traditional outcomes.Keywords
Funding Information
- Genentech (ML39789)
This publication has 23 references indexed in Scilit:
- Natalizumab Treatment Reduces Fatigue in Multiple Sclerosis. Results from the TYNERGY Trial; A Study in the Real Life SettingPLOS ONE, 2013
- Neuro-QOLNeurology, 2012
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteriaAnnals of Neurology, 2011
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple SclerosisNew England Journal of Medicine, 2006
- A review about the impact of multiple sclerosis on health-related quality of lifeDisability and Rehabilitation, 2003
- Using the SF-36 measure to compare the health impact of multiple sclerosis and Parkinson's disease with normal population health profilesJournal of Neurology, Neurosurgery & Psychiatry, 2003
- Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosisAnnals of Neurology, 1996
- Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 1995
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992